ERBB2 and breast cancer: For example, trastuzumab, a monoclonal antibody Erbb2 inhibitor used to treat Erbb2+ breast cancer, has been shown to lead to congestive heart failure in 1.7–4.1% of patients and a 10% decrease in LVEF when used alone as treatment32–34.